Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how clinical data and treatment selection in later-line HER2+ metastatic breast cancer are informed by the latest therapeutic advancements, including targeted therapies like trastuzumab deruxtecan (T-DXd) and tucatinib, to optimize patient outcomes and manage progression.
Panelists discuss how managing trastuzumab deruxtecan (T-DXd)–related toxicity and intolerance in later-line HER2+ breast cancer requires close monitoring, early detection of adverse effects like interstitial lung disease, and strategic adjustments to treatment regimens for improved patient safety and outcomes.
Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.
Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.
Panelists discuss the strategic screening and management of brain metastases in HER2+ breast cancer, focusing on current approaches and emerging strategies to address this complication.
Panelists discuss intracranial efficacy data with tucatinib and T-DXd in the treatment of brain metastases, highlighting key findings and their implications for clinical practice.
Panelists discuss a clinical scenario involving tucatinib-based regimens in the management of brain metastases in the second-line metastatic setting, exploring treatment options and clinical decision-making.
Panelists discuss evolving frontline treatment strategies and future directions in HER2+ breast cancer, focusing on the latest advancements and emerging approaches in managing this subtype.
The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.
